Cargando…

Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer’s disease: analysis of effects of baseline features on treatment response

BACKGROUND: Treatment of Alzheimer’s disease with acetylcholinesterase inhibitors can result in symptomatic benefits, but patients often show variable responses. The objective of this post hoc analysis was to investigate relationships between easily identifiable baseline characteristics/demographics...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sabbagh, Marwan, Cummings, Jeffrey, Christensen, Daniel, Doody, Rachelle, Farlow, Martin, Liu, Liang, Mackell, Joan, Fain, Randi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681558/ https://www.ncbi.nlm.nih.gov/pubmed/23742728 http://dx.doi.org/10.1186/1471-2318-13-56

Ejemplares similares

Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer's disease: evaluating the impact of baseline severity
por: Ferris, Steven, et al.
Publicado: (2013)

Progressive cholinergic decline in Alzheimer's Disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology
por: Sabbagh, Marwan, et al.
Publicado: (2011)

Long-term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer’s disease
por: Tariot, Pierre, et al.
Publicado: (2012)

Analyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer's disease
por: Ferris, Steven H, et al.
Publicado: (2011)

Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease
por: Farlow, Martin, et al.
Publicado: (2011)

Clinical Recommendations for the Use of Donepezil 23 mg in Moderate-to-Severe Alzheimer's Disease in the Asia-Pacific Region
por: Sabbagh, Marwan, et al.
Publicado: (2016)

Broader Considerations of Higher Doses of Donepezil in the Treatment of Mild, Moderate, and Severe Alzheimer's Disease
por: Berk, Camryn, et al.
Publicado: (2012)

Intepirdine as adjunctive therapy to donepezil for mild‐to‐moderate Alzheimer's disease: A randomized, placebo‐controlled, phase 3 clinical trial (MINDSET)
por: Lang, Frederick M., et al.
Publicado: (2021)

Donepezil Plus Solifenacin (CPC-201) Treatment for Alzheimer’s Disease
por: Chase, Thomas N., et al.
Publicado: (2017)

Safety and tolerability of donepezil 23 mg with or without intermediate dose titration in patients with Alzheimer’s disease taking donepezil 10 mg: a multicenter, randomized, open-label, parallel-design, three-arm, prospective trial
por: Hong, Yun Jeong, et al.
Publicado: (2019)

Cost‐effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO‐AD trial)
por: Knapp, Martin, et al.
Publicado: (2016)

Effects on caregiver burden of a donepezil hydrochloride dosage increase to 10 mg/day in patients with Alzheimer’s disease
por: Nakamura, Kazuhito, et al.
Publicado: (2014)

Effect of TTP488 in patients with mild to moderate Alzheimer’s disease
por: Burstein, Aaron H, et al.
Publicado: (2014)

Efficacy of Galantamine on Cognition in Mild-to-Moderate Alzheimer's Dementia after Failure to Respond to Donepezil
por: Hwang, Tae-Young, et al.
Publicado: (2016)

Effect of donepezil on transcranial magnetic stimulation parameters in Alzheimer's disease
por: Hwang, Yun Tae, et al.
Publicado: (2018)

Transdermal donepezil on the treatment of Alzheimer’s disease
por: Sozio, Piera, et al.
Publicado: (2012)

DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease – a multicentre RCT
por: Jones, Rob, et al.
Publicado: (2009)

Safety and efficacy of donepezil hydrochloride in patients with mild to moderate Alzheimer's disease: Findings of an observational study
por: Mehta, Suyog, et al.
Publicado: (2012)

Efficacy of Memantine, Donepezil, or Their Association in Moderate-Severe Alzheimer's Disease: A Review of Clinical Trials
por: Molino, Ivana, et al.
Publicado: (2013)

Donepezil Beyond Alzheimer's Disease? A Narrative Review of Therapeutic Potentials of Donepezil in Different Diseases
por: Pooladgar, Parham, et al.
Publicado: (2022)

A Randomized Double-blind Study to Assess the Skin Irritation and Sensitization Potential of a Once-weekly Donepezil Transdermal Delivery System in Healthy Volunteers
por: Sabbagh, Marwan N., et al.
Publicado: (2023)

A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer’s disease
por: Deardorff, William James, et al.
Publicado: (2016)

Peripheral and central effects of γ-secretase inhibition by semagacestat in Alzheimer’s disease
por: Doody, Rachelle S, et al.
Publicado: (2015)

The Effect of Choline Acetyltransferase Genotype on Donepezil Treatment Response in Patients with Alzheimer’s Disease
por: Lee, Kang Uk, et al.
Publicado: (2015)

Effect of QT Prolongation in Patients Taking Cholinesterase Inhibitors (Donepezil) for Alzheimer’s Disease
por: Kuwahata, So, et al.
Publicado: (2021)

Donepezil in Alzheimer’s disease: From conventional trials to pharmacogenetics
por: Cacabelos, Ramón
Publicado: (2007)

Donepezil enhances understanding of degraded speech in Alzheimer's disease
por: Hardy, Chris J. D., et al.
Publicado: (2017)

Donepezil Treatment for Alzheimer's Disease in Chronic Dialysis Patients
por: Yiannopoulou, Konstantina G., et al.
Publicado: (2019)

Speed of Improvement in Symptoms of Depression With Desvenlafaxine 50 mg and 100 mg Compared With Placebo in Patients With Major Depressive Disorder
por: Katzman, Martin A., et al.
Publicado: (2017)

The Effects of Donepezil on 15-Item Geriatric Depression Scale Structure in Patients with Alzheimer Disease
por: Yang, Youngsoon, et al.
Publicado: (2016)

Possible Preventive Effect of Donepezil and Hyoscyamoside by Reduction of Plaque Formation and Neuroinflammation in Alzheimer's Disease
por: Soureshjani, Fatemeh Heidari, et al.
Publicado: (2021)

Alzheimer's disease drug development pipeline: 2019
por: Cummings, Jeffrey, et al.
Publicado: (2019)

Alzheimer's disease drug development pipeline: 2020
por: Cummings, Jeffrey, et al.
Publicado: (2020)

Studies on Interaction of Buffalo Brain Cystatin with Donepezil: An Alzheimer's Drug
por: Amin, Fakhra, et al.
Publicado: (2013)

Multi-Target Directed Donepezil-Like Ligands for Alzheimer's Disease
por: Unzeta, Mercedes, et al.
Publicado: (2016)

Commentary: Donepezil enhances understanding of degraded speech in Alzheimer's disease
por: Campbell, Tom A., et al.
Publicado: (2018)

Collaborative research between academia and industry using a large clinical trial database: a case study in Alzheimer's disease
por: Jones, Roy, et al.
Publicado: (2011)

Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer's disease in Germany using discrete event simulation
por: Hartz, Susanne, et al.
Publicado: (2012)

Effect of donepezil on Hcy level in serum of Alzheimer's disease patients and correlation analysis of Hcy and dyssomnia
por: Liu, Xinxin, et al.
Publicado: (2019)

Modulation of Brain Activity and Functional Connectivity by Acupuncture Combined With Donepezil on Mild-to-Moderate Alzheimer's Disease: A Neuroimaging Pilot Study
por: Zhan, Yijun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kt429ll3hvg54eh99to574ralt